Search

Your search keyword '"Kawakami, Shohei"' showing total 12 results
Start Over Author "Kawakami, Shohei" Search Limiters Full Text
12 results on '"Kawakami, Shohei"'

4. Phellinus linteus及びFuscoporia obliqua菌糸体粗水抽出物のin vitroにおける抗酸化能の評価

Author

Kawakami, Shohei and Saito, Takashi

Subjects
Phellinus linteus, Fuscoporia obliqua, fungi, antioxidant activity, equipment and supplies, myceliums
Abstract

application/pdf, Cancer is one of the causes of death and is increasing year by year in Japan. So, demands for functional food increase for health maintenance to prevent cancer. Mushroom such as Phellinus linteus and Fuscoporia obliqua are known to be functional foods with anti-carcinogenic action. Because the growth of the mycelium is faster than that of the fruit body of the mushroom, radical scavenging activity, leading to causes of cancer initiation, was measured with those mycelial extracts. Mycelia of Phellinus linteus and Fuscoporia obliqua were cultured, and those aqueous extracts were prepared. As a result, it was found that Phellinus linteus mycelium had a higher antioxidant active ability than Fuscoporia obliqua mycelium. However, it was also found that the antioxidant active of those fruit body extracts was higher than those of mycelia extracts.

Published
2022

7. A Case of Composite Lymphoma with Extranodal NK/T-cell Lymphoma, Nasal-type and Diffuse Large B-cell Lymphoma

Author

Kawai, Hidetsugu, primary, Matsushita, Hiromichi, additional, Kawakami, Shohei, additional, Furuya, Daisuke, additional, Shiraiwa-Hara, Sawako, additional, Ichiki, Akifumi, additional, Hara, Ryujiro, additional, Aoyama, Yasuyuki, additional, Ogiya, Daisuke, additional, Suzuki, Rikio, additional, Machida, Shinichiro, additional, Onizuka, Makoto, additional, Shirasugi, Yukari, additional, Ogawa, Yoshiaki, additional, Kawada, Hiroshi, additional, Nakamura, Naoya, additional, and Ando, Kiyoshi, additional

Published
2019
Full Text
View/download PDF

10. Late Kidney Injury After Admission to Intensive Care Unit for Acute Heart Failure.

Author

Morooka M, Shirakabe A, Okazaki H, Matsushita M, Shigihara S, Nishigoori S, Sawatani T, Tani K, Kiuchi K, Kawakami S, Michiura Y, Kamitani S, Kobayashi N, and Asai K

Subjects
Humans, Male, Female, Aged, Retrospective Studies, Creatinine blood, Middle Aged, Acute Disease, Aged, 80 and over, Hospitalization statistics & numerical data, Risk Factors, Follow-Up Studies, Time Factors, Heart Failure epidemiology, Heart Failure complications, Acute Kidney Injury epidemiology, Acute Kidney Injury etiology, Acute Kidney Injury therapy, Intensive Care Units statistics & numerical data
Abstract

Late kidney injury (LKI) in patients with acute heart failure (AHF) requiring intensive care is poorly understood.We analyzed 821 patients with AHF who required intensive care. We defined LKI based on the ratio of the creatinine level 1 year after admission for AHF to the baseline creatinine level. The patients were categorized into 4 groups based on this ratio: no-LKI (< 1.5, n = 509), Class R (risk; ≥ 1.5, n = 214), Class I (injury; ≥ 2.0, n = 78), and Class F (failure; ≥ 3.0, n = 20). Median follow-up after admission for AHF was 385 (346-426) days. Multivariate logistic regression analysis revealed that acute kidney injury (AKI) during hospitalization (Class R, odds ratio [OR]: 1.710, 95% confidence interval [CI]: 1.138-2.571, P = 0.010; Class I, OR: 6.744, 95% CI: 3.739-12.163, P < 0.001; and Class F, OR: 9.259, 95% CI: 4.078-18.400, P < 0.001) was independently associated with LKI. Multivariate Cox regression analysis showed that LKI was an independent predictor of 3-year all-cause death after final follow-up (hazard ratio: 1.545, 95% CI: 1.099-2.172, P = 0.012). The rate of all-cause death was significantly lower in the no-AKI/no-LKI group than in the no-AKI/LKI group (P = 0.048) and in the AKI/no-LKI group than in the AKI/LKI group (P = 0.017).The incidence of LKI was influenced by the presence of AKI during hospitalization, and was associated with poor outcomes within 3 years of final follow-up. In the absence of LKI, AKI during hospitalization for AHF was not associated with a poor outcome.

Published
2024
Full Text
View/download PDF

11. Fibrinogen-to-Albumin Ratio in Patients with Acute Heart Failure.

Author

Sawatani T, Shirakabe A, Shighihara S, Nishigoori S, Kiuchi K, Tani K, Kawakami S, Michiura Y, Kamitani S, Otsuka T, Kobayashi N, and Asai K

Subjects
Humans, Male, Female, Aged, Acute Disease, Serum Albumin metabolism, Serum Albumin analysis, Middle Aged, Retrospective Studies, Aged, 80 and over, Prognosis, Biomarkers blood, C-Reactive Protein analysis, C-Reactive Protein metabolism, Heart Failure blood, Heart Failure mortality, Fibrinogen analysis, Fibrinogen metabolism
Abstract

The fibrinogen-to-albumin ratio (FAR) in the acute phase of acute heart failure (AHF) has seldom been evaluated.A total of 1,402 hospitalized AHF patients were analyzed. We calculated FAR using the following formula: plasma fibrinogen (g/L) /serum albumin (g/L) × 1,000. Patients were divided into 3 groups according to FAR value quartiles (low-FAR [Q1, FAR ≤ 564, n = 352], middle-FAR [Q2/Q3, 565 ≤ FAR ≤ 1,071, n = 700], and high-FAR [Q4, FAR ≥ 1,072, n = 350]). The median (interquartile range) FAR value was 855 (710-1,103). A multivariate logistic regression model showed that C-reactive protein (per 1 mg/dL increase; odds ratio [OR]: 1.307, 95% CI: 1.250-1.3366, P < 0.001), ischemic heart disease etiology (OR: 1.691, 95%CI: 1.227-2.331, P = 0.001), and diabetes mellitus (DM; OR: 1.624, 95%CI: 1.188-2.220, P = 0.002) were independently associated with high FAR values. Kaplan-Meier curve analysis showed that prognosis of all-cause mortality within 730 days was significantly poorer (P = 0.033) in the high-FAR group than in the other 2 groups. Conversely, in the low-albumin group, the prognosis of all-cause mortality was significantly poorer (P = 0.006) in the low-FAR group than in the other groups. A Cox regression model revealed that in the low-albumin group, a low FAR value was an independent predictor of 730-day mortality (hazard ratio [HR]: 0.503, 95% CI: 0.287-0.881, P = 0.016) and HF events (HR: 0.444, 95%CI 0.276-0.712, P = 0.001).Elevated FAR was associated with inflammation, DM, and ischemic etiology, and with adverse outcomes in the whole AHF group, whereas low FAR was independently associated with adverse outcomes in the low-albumin group.

Published
2024
Full Text
View/download PDF

12. Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide.

Author

Toyosaki M, Onizuka M, Amaki J, Shiraiwa S, Aoyama Y, Machida S, Kawai H, Murayama H, Ogiya D, Matsui K, Kawakami S, Harada K, Kondo Y, Hirabayashi K, Nakamura N, Ogawa Y, Kawada H, and Ando K

Abstract

Neurological complications after hematopoietic stem cell transplantation (HSCT) are frequently life-threatening, and their clinical management can be highly challenging. In the case of central nervous system lesions post-HSCT, a definitive diagnosis is often difficult to reach because many different causative and contributing conditions may be present, including bacterial, fungal, or viral infections; original disease relapse; and post-transplant lymphoproliferative disorder (PTLD). Here, we report a case of a 32-year-old male patient with Philadelphia chromosomepositive acute lymphoid leukemia who underwent three HSCTs and was then diagnosed with primary central nervous system (PCNS) PTLD by brain biopsy. The third HSCT was a haplo-identical peripheral blood stem cell transplantation from his mother, with post-transplant high-dose cyclophosphamide and tacrolimus used as graft-versus-host disease prophylaxis. Four months after the HSCT, multiple small ring lesions were detected in the parabasal ganglia of the patient's brain during magnetic resonance imaging. A lesion biopsy indicated Epstein-Barr virus (EBV)-positive, diffuse large B-cell lymphoma. Because the patient had no evidence of systemic lymphadenopathy, we diagnosed him with PCNS-PTLD. There was no EBV DNA in this patient's cerebrospinal fluid. The diagnosis of PCNS-PTLD by EBV DNA polymerase chain reaction is difficult and highlights the importance of a brain biopsy to diagnose PCNS-PTLD, especially in cases showing no EBV DNA in the cerebrospinal fluid. Although a rare condition, it is essential to locate and analyze cases of PCNS-PTLD after HSCT to establish the optimal strategy for treatment or prophylaxis., Competing Interests: The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website., (Copyright Ⓒ2018 Asia-Pacific Blood and Marrow Transplantation Group (APBMT).)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results